Ziff, Oliver J. http://orcid.org/0000-0002-1504-7245
Neeves, Jacob
Mitchell, Jamie
Tyzack, Giulia http://orcid.org/0000-0001-5730-2112
Martinez-Ruiz, Carlos http://orcid.org/0000-0002-4817-0565
Luisier, Raphaelle
Chakrabarti, Anob M. http://orcid.org/0000-0002-6841-5718
McGranahan, Nicholas http://orcid.org/0000-0001-9537-4045
Litchfield, Kevin
Boulton, Simon J. http://orcid.org/0000-0001-6936-6834
Al-Chalabi, Ammar http://orcid.org/0000-0002-4924-7712
Kelly, Gavin http://orcid.org/0000-0001-7219-560X
Humphrey, Jack http://orcid.org/0000-0002-6274-6620
Patani, Rickie http://orcid.org/0000-0002-3825-7675
Article History
Received: 9 September 2022
Accepted: 22 March 2023
First Online: 20 April 2023
Competing interests
: N.M. has stock options in and has consulted for Achilles Therapeutics and holds European patents relating to targeting neoantigens (PCT/EP2016/ 059401), identifying patient response to immune checkpoint blockade (PCT/ EP2016/071471), determining HLA LOH (PCT/GB2018/052004), predicting survival rates of patients with cancer (PCT/GB2020/050221). The remaining authors have no conflicts of interest.